COVID-19 has left a trail of uncertainty in its wake as the burden weighing on pharmaceutical companies working to get their clinical trials back on track appears somewhat insurmountable. These challenges facing the pharmaceutical industry are multifaceted as the number of trials previously put on hold now looking to reconvene is compounded by the growing backlog of new trials waiting to begin. Not only that, but the considerable influx of COVID-19 trials increases this burden further. For trials moving forward amidst COVID-19, the answer has been adaptation, and that will continue to hold true as more trials look to begin and resume.
From what has been see thus far, the adoption of new technologies and techniques for running clinical trials has paved the way for a “new normal” in the industry. This “new normal”, forged by the need to adjust, has not only allowed trial processes to continue, but has also spurred efficiency improvements that will continue to persist and grow.
The collection of patient data has seen a large boost with the integration of Telehealth. What was once a very arduous task for the patient, involving constant travel to trial sites to record relevant data is now, in many cases, as easy as calling in from a patient’s home. And while there are still be instances in which patients will need to travel on-site, this capability offers the opportunity for more consistent retrieval of data that would otherwise be uncollected.
The ability to remotely collect patient data has clear significance, and the capacity to execute virtual audits is equally as important when it comes to trial execution amidst the “new normal”. When done remotely, audits have seen overall efficiency increases, proving that updating processes to be digitally capable is of paramount importance.
Now, more than ever, sponsors and sites should be focused on digitally adapting their processes to ensure their continued clinical trial success. As this process can be a daunting one to tackle alone, bringing in a trusted partner can greatly ease any difficulties. Transitioning to remote site audits is a great way to help you and your team stay on track, and MVG is the perfect partner to make that goal a reality.
MVG Consulting Services specializes in helping small to medium sized biotechnology and pharmaceutical companies with their clinical development programs and we can provide start-up and virtual companies with the necessary resources to begin their clinical development program.
Services include:
- Clinical Research Consulting Services
- Clinical Trial Development
- Project Rescue
- Inspection Readiness
MVG provides highly qualified clinical research professionals who seamlessly become a part of your project team. Additionally, we provide virtual companies with an entire project team that encompasses all aspects of clinical development.
We invite you to fill out the form below to learn more about how MVG Consulting can help you with your clinical devleopment needs.
